Remove Antibody Remove FDA Approval Remove Protein
article thumbnail

FDA approves bispecific drug from Pfizer for multiple myeloma

Bio Pharma Dive

Elrexfio is the third bispecific antibody cleared to treat the blood cancer, and will compete with other therapies that target the “BCMA” protein on myeloma cells.

article thumbnail

FDA approves Amgen drug for tough-to-treat form of lung cancer

Bio Pharma Dive

Imdelltra, a bispecific antibody targeting a protein called DLL3, is cleared for use following chemotherapy in treating extensive-stage small cell lung cancer.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Roche follows AbbVie with FDA approval for dual-targeting lymphoma drug

Bio Pharma Dive

The approval of Columvi adds another “bispecific antibody” to the market, highlighting the fast research progress for drugs that target two proteins rather than one.

article thumbnail

Roche gets FDA approval for HER2 breast cancer diagnostic

pharmaphorum

Roche’s PATHWAY anti-HER2/neu (4B5) Rabbit Monoclonal Primary Antibody test becomes the only FDA approved companion diagnostic indicated to aid assessment of HER2 low-metastatic breast cancer patients. HER2 is a receptor protein that accelerates cancer cell growth.

article thumbnail

FDA grants accelerated approval for ImmunoGen’s ovarian cancer ADC

Pharmaceutical Technology

The US Food and Drug Administration (FDA) has granted accelerated approval for ImmunoGen’s Elahere (mirvetuximab soravtansine-gynx) to treat adults with folate receptor alpha (FR?)-positive, binding antibody, a cell-surface protein which is greatly expressed in ovarian cancer, as well as the maytansinoid payload DM4.

Antibody 246
article thumbnail

FDA approves Alentis’ IND for ALE.C04 to treat CLDN1+ tumours

Pharmaceutical Technology

Alentis Therapeutics has received US Food and Drug Administration (FDA) clearance for its investigational new drug (IND) application for ALE.C04 to treat Claudin-1 positive (CLDN1+) tumours. ALE.C04 is an investigational antibody designed to target exposed CLDN1 in cancer cells.

article thumbnail

US FDA grants approval for AstraZeneca’s combination liver cancer therapy

Pharmaceutical Technology

A human monoclonal antibody, Imfinzi attaches to the PD-L1 protein and hinders the PD-L1 interaction with the PD-1 and CD80 proteins. Imjudo is also a human monoclonal antibody and hinders cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) activity.

Protein 173